Yes if CEO Dixon can sell off QM or NS at this exact stage one has gotta think either would easily garner TSOI something north of +$10M...and as long as it's remotely close to $20M then TSOI could forego any big pharma collaborative partner and pay the JadiCell phase III trial costs themselves.
Lots of crazy potential in play behind the scenes these days...so it's a very good thing that CEO Dixon and Dr. Ichim have such a strong Advisory Board to lean on and help them navigate the best pathway forward.
News 
Market Data 
Discover 
